Terbutaline inhalations by the turbuhaler® as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease  by Hansen, N.C.G. et al.
Respiratory Medicine (1994) 88, 267-27 1 
Original Articles 
Terbutaline inhalations by the Turbuhaler@ as 
replacement for domiciliary nebulizer therapy in severe 
chronic obstructive pulmonary disease 
N. C. G. HANSEN*& T. BVALDt AND T. B. IBSEN$ 
Department of Respiratory Diseases, Odense University Hospital, Odense, tDepartment of Respiratory 
Diseases P, Bispebjerg Hospital, Copenhagen, and IMedical Department, 
ASTRA, Denmark 
Patients with chronic obstructive pulmonary disease (COPD) are often treated with high dose inhalations of 
&agonists. We compared domiciliary therapy with terbutaline administered by the Turbuhaler@ and by a jet 
nebulizer. Forty nebulizer users with severe COPD were included in the randomized, double-blind, cross-over 
study. Terbutaline was inhaled t.i.d. for 2 weeks as dry powder (5 doses=2.5 mg) by Turbuhaler@ or as 
solution (2 ml=5 mg) by jet nebulizer (Pari Inhalierboy@). The mean age of the 25 completing patients was 66 
years (range: 54-81) the mean FEV, was 0.73 1 or 29% of predicted (range: 1 l-55%). The period where the 
Turbuhaler@ delivered the active drug was preferred by 16 patients, the nebulizer period by seven (P=O.O9). 
The median score concerning feeling of control over the disease - according to the Chronic Respiratory 
Disease Questionnaire - was better after the Turbuhalera period (P=O.Ol). Other scores concerning disease 
related quality of life, the daily peak expiratory flow rates, the additional use of a metered dose inhaler were 
not significantly different for the two types of treatment. It is concluded that high dose domiciliary terbutaline 
treatment by Turbuhaler@ can replace nebulizer treatment in most patients with severe COPD. 
Introduction 
The aim of the present study was to compare self 
administered domiciliary terbutaline therapy by the 
Turbuhaler@ and by a jet nebulizer in COPD 
patients, who already were on nebulizer therapy. The 
use of domiciliary nebulizers for administration of 
high doses of bronchodilators remains controversial 
(1). In patients with COPD it has been shown that 
domiciliary &agonist therapy by a nebulizer can be 
matched by a pressurized metered dose inhaler 
(MDI) with a 750 ml spacer (2) and even by the MD1 
alone (3,4). The forced expiratory volume in one 
second (FEV,) and the forced vital capacity (FVC) 
were found to increase equally well after inhalation 
of 2 mg terbutaline (four doses) by Turbuhaler@ and 
5 mg terbutaline from a jet nebulizer when COPD 
patients inhaled under surveillance of a nurse (5). 
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Most studies on bronchodilators have used changes 
in the forced expiratory volume as indicators of 
effect. However, an earlier study found that the 
subjective relief from terbutaline by a domiciliary 
nebulizer was unrelated to the reversibility of the 
airways obstruction in COPD patients (6), and we 
decided to focus on the subjective relief from the 
inhalation therapy. 
Patients and Methods 
The inclusion criteria were: (a) Domiciliary nebu- 
lizer therapy with &agonists daily for at least the 
previous month, (b) COPD -defined according to 
American Thoracic Society criteria (7) with 
FEV, 5 50% of predicted (national reference values 
as recommended by the Danish Thoracic Society) - 
at the most recent test in a stable phase. There were 
no demands for a specified increase in FEV, after a 
bronchodilator. Users of long term oxygen therapy 
were not considered for inclusion. Patients with 
COPD in an unstable phase were likewise not 
included. The study was in accordance with the 
0 1994 W. B. Saunders Company Ltd. 
268 N. C. G. Hansen et al. 
Helsinki Declaration II, and was approved by the 
local Ethical Committee. 
A randomized, double-blind, cross-over design 
with a double dummy technique was used. After a 1 
week run-in period the patients were randomized to 2 
weeks with either treatment A or B followed by 2 
weeks with the other. Treatment A was 2.5 mg 
terbutaline powder (five doses) by Bricanyl@ 
Turbuhaler@+2 ml nebulized isotonic saline three 
times daily, while treatment B was 2.5 mg lactose 
powder by Turbuhaler@+2 ml (5 mg) nebulized terb- 
utaline (Bricanyl@) three times daily. We attempted 
to give equipotent doses of terbutaline as in the 
previous study (5), and increased the powder dosage 
from 2.0 mg to 2.5 mg, as the patients should admin- 
ister the powder inhaler by themselves. The patients 
continued to inhale by face mask from their own 
nebulizer: the Pari Inhalierboy@, a jet nebulizer 
driven by an electrical compressor (the most fre- 
quently used brand of nebulizer in Denmark). The 
patients took one powder dose by maximal inspira- 
tion through the powder inhaler after every 10 tidal 
inspirations from the nebulizer, and after the five 
powder doses the nebulizer was used until ‘dryness’. 
Oral therapy was not changed during the treatment 
periods, and a terbutaline MD1 was used if extra 
medication was needed. 
After each of the two treatment periods a trained 
nurse visited the patient. The preferred treatment 
period was recorded, the general condition marked 
on a visual analogue scale, and the disease related 
quality of life measured by a Danish translation of 
the Chronic Respiratory Disease Questionnaire (8). 
At each visit the patient took the same type of 
inhalation as during the preceding 2 weeks. FEV, 
and FVC were measured by a portable pneumo- 
tachograph (Vitalograph Compact@) before and 5, 
15, 30 and 60 min after the treatment. The peak 
inspiratory flow (PIF) and the forced inspiratory 
volume (FIV) through the powder inhaler were 
measured by the pneumotachograph during the 
inhalations. The patients monitored the peak expira- 
tory flow (PEF) before and immediately after each of 
the three daily treatments (Mini Wright Peak Flow 
Meter) and recorded the results in a diary together 
with the number of extra puffs from the MDI. The 
use of the Turbuhaler@ was evaluated by weighing 
and by checking the position of the indicator wheel. 
The emptied ampules of nebulizer solution were 
counted. Poor compliance was defined as inhalation 
of more than 125% or less than 75% of the prescribed 
dosage. 
The data analysis showed no significant signs of a 
carry-over effect or a period effect (9) and paired 
Table I Baseline FEV, and FVC (at inclusion into the 
study), peak inspiratory flow (PIF) and forced inspiratory 
volume (FIV) through the active Turbuhaler@ (average of 5 
inhalations for each patient) for the 25 completing patients 
Mean Range 
FEV, (1): 
FEV, (% predicted) 
FVC (1); 
FVC (% predicted) 
PIF through the 
0.73 (0.28-1.25) 
29 (1 l-55) 
1.72 (0.95-3.30) 
51 (30-77) 
Turbuhaler@ (1 min- ‘) 
FIV through the 
47 (2465) 
Turbuhaler@ (1): 1.44 (0.67-2.79) 
Table 2 General condition after 2 weeks with the two types 
of active treatment as scores on visual analogue scales 
Median Range 
Turbuhaler@ 
Pari Inhalierboy@ 
Difference 
67 l-100 
48 7-99 
(powder inhaler minus nebulizer) 6 - 52-64 
*The patients answered the question: ‘How was your health 
during the last 2 weeks ~ everything considered?‘, 
0 mm=‘worst possible’, 100 mm=‘best possible’. 
PzO.1485, Wilcoxon signed-ranks test, 95% confidence 
interval of the median difference: - 3 to +25). 
statistical analysis were applied. When a Gaussian 
distribution of the variable in question could not be 
excluded a parametric test was performed. Otherwise 
non-parametric tests were applied. Many zero- 
differences occurred between the two treatment 
periods when the quality of life parameters were 
analysed, and we applied the one-sample Wilcoxon 
test modified as suggested by Pratt (10). 
Results 
Fifteen of the 40 included patients did not com- 
plete the study according to the protocol: eight 
patients due to exacerbation of the COPD (five 
during active Turbuhalera treatment), six due to 
poor compliance, and one patient due to malfunc- 
tion of the nebulizer. There were no statistically 
significant differences between completers and 
non-completers concerning age, smoking habits, 
duration of nebulizer therapy prior to the study, or 
maintenance therapy, FEV,, FVC (before and after 
terbutaline), or PEF during the run-in period. 
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Table 3 Results from the Chronic Respiratory Questionnaire: Median scores at interviews after 2 weeks treatment 
Active treatment by 95% confidence 
Median interval of the 
Powder inhaler Nebulizer n difference difference P 
Shortness of breath 16.0 17.0 23 0.0 - 3-l 0.591 
Fatigue 14.0 14.0 24 0.3 o-2 0.109 
Physical function 33-o 31.0 23 0.7 -4-3 0.976 
Emotional function 35.5 32.0 24 0.0 - 2-2 0.633 
Mastery 23.0 21.5 24 0.3 o-2 0.008* 
Psychological function 55.0 52.5 24 1.0 -14 O-104 
Total score 108.0 106.0 23 3.0 - 3-5 0.322 
Higher scores=better condition. The possible ranges of the scores were 5-35 (shortness of breath), 4-28 (fatigue), 749 
(emotional function), 428 (mastery). The score for physical function was calculated by adding the scores for dyspnoea and 
fatigue, while the score for psychological function was calculated by adding the scores for emotional function and mastery. 
The median scores are compared by Wilcoxon-Pratt test. 
Table 4 Mean baseline peak expiratory flow, mean increase after inhalation and 95% confidence 
intervals of the differences (Turbuhaler@ minus Pari Inhalierboya). For each of the 25 patients the 
average values from the 2 weeks with each treatment are used 
Powder inhaler Nebulizer 
P 95% confidence interval 
t- test of the mean difference 
Before inhalation (I min- ‘) 
Morning 165 
Afternoon 177 
Evening 175 
167 0,542 - 7-3 
178 0,783 - 7-5 
174 0.803 - 557 
Increase (% over value before inhalation) 
Morning 16 15 0.101 CL4 
Afternoon 13 12 0.633 - 1-3 
Evening 11 11 0.306 -1-2 
The 25 completing patients (16 women and 9 
men) had a mean age of 66 years (range; 5481 
years). The median duration of the domiciliary 
nebulizer therapy prior to the study was 19 months 
(range: l-79 months). The data from the baseline 
expiratory lung function tests and the data from the 
inspirations through the Turbuhaler’a are shown in 
Table 1. Sixteen patients (70%) preferred the period 
where the powder inhaler had been active, while 
seven preferred the active nebulizer period 
(PzO.093 1, binomial test, 95% confidence interval 
for the preference for Turbuhaler? 47-87%). The 
median visual analogue scores concerning the gen- 
eral health condition was higher after the active 
Turbuhaler@ period, but the difference was not 
statistically significant (Table 2). The median score 
concerning feeling of control over the chronic dis- 
ease, was slightly better after the active powder 
inhaler period, and this difference was statistically 
significant. However, the summarized scores con- 
cerning physical and emotional function were the 
same after the two types of treatment (Table 3). 
Baseline PEF and increase in PEF after inhalation 
were not different for the two types of treatment 
(Table 4). The baseline FEV, and FVC were not 
different after the two treatment periods nor were 
the increases in FEV, or FVC different (Table 5). 
Additional use of MD1 and the number of reported 
side effects were not different for the two types of 
treatment. It was not possible to predict the pre- 
ferred treatment from the age of the patient, the 
baseline FEV,, FVC or from the PIF obtained 
through the Turbuhaler@. 
Discussion 
The included patients constituted about 50% of the 
local nebulizer users fulfilling the inclusion criteria. 
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Table 5 Mean baseline FEV, and FVC and the mean maximal increase over baseline after 
inhalation at the end of the two treatment periods 
Nebulizer Powder inhaler 
95% confidence interval 
of the mean difference 
FEV, (1) 
FVC (1) 
Maximal FEV, increase (“!) 
Maximal FVC increase (%) 
0.69 0.68 - 0~0330~05 
1.67 1.68 -0.13-0.11 
24.2 26.0 - 7.2-3,6 
33.0 33.9 - 53-7.1 
Participants in the study were on average 7 years 
younger and had on average used the nebulizer for a 
shorter period of time than non-participants. How- 
ever, the recorded lung function data were not differ- 
ent for participants and non-participants. There were 
no provable differences between the completers and 
the non-completers, and the withdrawals were 
equally distributed between the two types of treat- 
ment, which suggests that the conclusions would 
have been the same if more patients had completed 
the study. 
The statistically significant feeling of better control 
over the chronic disease during the Turbuhale@ 
period seems not to have been obtained by chance. 
The score was calculated from four independent 
answers, and the differences between two of these 
were statistically significant, while the other two 
answers showed the same tendency. Furthermore, the 
preference data and the scores on visual analogue 
scales concerning general condition, also showed a 
tendency towards a better effect from the powder 
inhaler. 
Judged by the 95% confidence intervals of the 
differences between the remaining quality of life 
parameters the statistical power of the study was 
sufficient to exclude differences of clinical import- 
ance. Guyatt et al. considered an increase in score for 
physical function of four points or more as clinically 
important (11). 
It was considered impossible to include a period 
without active treatment in the present study, as all 
the patients used the nebulizer daily before the study. 
The present study is unable to evaluate the possible 
benefit from adding treatment with fixed high doses 
of bronchodilators in patients with severe COPD. 
The participants were characterized by daily use of 
the nebulizer for a long time, suggesting at least 
substantial subjective relief in this selected group. 
From the result in this group of selected nebulizer 
users we conclude that most elderly patients with 
severe COPD will be able to treat themselves with 
terbutaline by Turbuhaler@ with at least the same 
benefit as they would obtain from domiciliary treat- 
ment by a jet nebulizer. Severe chronic obstruction of 
the airways does not prevent the use of the powder 
inhaler, and this treatment should be considered 
instead of the prescription of a domiciliary nebulizer. 
The costs of dry powder treatment are considerably 
less than the costs of domiciliary nebulizer therapy. 
Furthermore, the patients will benefit from the con- 
venient size of the dry powder device and the short 
duration of each treatment session. 
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